** Shares of cell-based therapy co THMO.O fall as much as
20.7% to $3.75 in early trade - lowest in more than 4 months
** Co, on Friday, posted Q2 rev of $2.2 mln, nearly half
from a year earlier; attributed decline to low demand for its
proprietary AXP disposable blood processing sets urn:newsml:reuters.com:*:nPn78SC1Sa
** THMO posted loss of $2.6 mln vs profit of $2 mln a year
earlier; co said loss was driven by inventory reserve of ~$3.6
mln for remaining on-hand COVID-19 testing kits from ImmuneCyte
recognized during quarter
** THMO becomes second-worst performer on NASDAQ
** YTD, stock up 7.5%
(Reporting by Shreyasee Raj in Bengaluru)
((Shreyasee.Raj@thomsonreuters.com;))